Scarica l'app Stockscreener
2.255
4.04%
-0.095
Dopo l'orario di chiusura:
2.26
0.005
+0.22%
Precedente Chiudi:
$2.35
Aprire:
$2.3
Volume 24 ore:
23,378
Relative Volume:
0.27
Capitalizzazione di mercato:
$10.28M
Reddito:
-
Utile/perdita netta:
$-2.17M
Rapporto P/E:
-0.13
EPS:
-17.3434
Flusso di cassa netto:
$-4.82M
1 W Prestazione:
-8.70%
1M Prestazione:
-20.32%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.18
$2.35
Intervallo di 1 settimana:
$1.8299
$2.465
Portata 52W:
$1.8299
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
2.255 | 10.28M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Newcelx Ltd Borsa (NCEL) Ultime notizie
NCEL SEC FilingsNewcelX Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NewcelX Ltd.Ordinary Shares (NQ: NCEL - The Chronicle-Journal
NewcelX raises $1.35M in private placement at 30% premium By Investing.com - Investing.com Australia
NewcelX Raises $1.35 Million in Premium-Priced Private Placement to Advance Type 1 Diabetes Program - tipranks.com
NewcelX Ltd. announced that it expects to receive $1.349994 million in funding - MarketScreener
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing - bitget.com
NewcelX raises $1.35M in private placement at 30% premium - Investing.com
NewcelX Ltd. Secures $2.7 Million in Private Placement to Advance Type 1 Diabetes Program - Quiver Quantitative
NewcelX raises fresh cash for Type 1 diabetes program in premium deal - Stock Titan
NCEL Should I Buy - Intellectia AI
Latest NLSPW NewsNLS Pharmaceutics to Participate in the Be... - Stock Titan
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy - Nasdaq
NewcelX and Eledon join forces to advance potential Type 1 diabetes cure - Indian Pharma Post
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
NewcelX and Eledon partner for NCEL-101 programme - Pharmaceutical Business review -
NewcelX (NCEL) Stock Analysis Report | Financials & Insights - Benzinga Japan
Newcelx partners with Eledon to advance NCEL-101 - BioWorld MedTech
NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes - Contract Pharma
NewcelX Forms Eledon Alliance to Accelerate NCEL-101 Diabetes Program - TipRanks
NewcelX partners with Eledon on type 1 diabetes therapy - Investing.com
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PR Newswire
NLSPW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NCEL | NewcelX Ltd. Ordinary Shares Institutional Ownership - Quiver Quantitative
NCEL | NewcelX Ltd. Ordinary Shares Stock Data, Price & News - Quiver Quantitative
NewcelX Cites Peer-Reviewed Mazindol Data as It Advances CVR-Linked Asset Talks - TipRanks
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences - Finviz
NewcelX Updates Corporate Presentation as It Sharpens Focus on Type 1 Diabetes Cell Therapies - TipRanks
NewcelX Announce Positive Results from International Collaborati - GuruFocus
NewcelX Reports Positive International Study Results on Biomaterial-Based Islet Delivery for Type 1 Diabetes - TipRanks
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression - marketscreener.com
Newcelx Ltd. Announces Positive Results from International Collaborative Study - marketscreener.com
NLS Pharmaceutics Announces Reverse Share Split and Name Change Amid Merger - MSN
NewCelX Appoints EY as New Auditor Following Merger - MSN
NewcelX appoints Swiss pharma executive to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX adds Swiss diabetes leader to advisory board to steer IsletRx program - MSN
NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board - marketscreener.com
NewcelX Adds Swiss Diabetes Leader to Advisory Board to Steer IsletRx Program - TipRanks
NewcelX appoints Swiss pharma executive to scientific advisory board - Investing.com
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - Barchart.com
Should I buy NewcelX Ltd. (NCEL) - Zacks Investment Research
What is the current Price Target and Forecast for NewcelX Ltd. (NCEL) - Zacks Investment Research
NewcelX Ltd. (NCEL) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Newcelx Ltd. Share Price (NCEL.US) - London South East
NewcelX Strengthens IP Portfolio with Chinese Patent Publication - TipRanks
NewcelX strengthens IP portfolio with Chinese patent publication - MSN
NewcelX patent for neurological disease treatments published in China - Investing.com
NewcelX patent for neurological disease treatments published in China By Investing.com - Investing.com Canada
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Nasdaq
NCEL|NewcelX Ord Shs|Price:2.490|Chg%:0.12 - TradingKey
NewcelX Ltd. (NCEL) -8.5% in After-hours: Decline Amid Routine Trading Conditions - Stocks Telegraph
NLSP SEC FilingsNls Pharmaceutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Newcelx Ltd Azioni (NCEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):